Skip to main content
Smart Investors Daily
OB

NASDAQ · OBIO

Orchestra BioMed Holdings, Inc.

Healthcare · Biotechnology

$6.58

Down-$0.42 (-6.00%)

Updated Nov 21, 2026, 7:37 PM

SID Score

6.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
257.76M
P/E ratio
-2.51
Dividend yield
0.00%
52-week range
$3.46 – $7.83
Volume
554.42K
Avg. volume
309.78K

Price performance · OBIO

OBIO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

OBIO closed at $6.58 after 21 trading sessions, up 17.71% for the selected period.

Last close
$6.58
Period change
+17.71%
Period low
$5.55
Period high
$7.46
Daily close
View OHLC price history
OBIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$6.89$7.17$6.47$6.58554.42K
Nov 19, 2026$7.50$7.63$6.96$7.00479.81K
Nov 18, 2026$7.02$7.825$7.00$7.461.2M
Nov 17, 2026$7.10$7.365$6.95$6.97552.14K
Nov 16, 2026$7.16$7.45$7.04$7.12755.59K
Nov 13, 2026$6.25$7.365$6.00$7.251.57M
Nov 12, 2026$5.99$6.18$5.70$6.15631.08K
Nov 11, 2026$5.75$6.34$5.705$6.01452.9K
Nov 10, 2026$5.83$5.905$5.69$5.73485.54K
Nov 9, 2026$5.73$5.88$5.36$5.70785.15K
Nov 6, 2026$5.135$6.04$5.10$5.681.74M
Nov 5, 2026$6.00$6.00$5.60$5.62258.71K
Nov 4, 2026$5.815$6.1609$5.745$6.00335.41K
Nov 3, 2026$5.70$5.98$5.52$5.56273.21K
Nov 2, 2026$5.92$6.02$5.66$5.69317.5K
Oct 30, 2026$6.07$6.075$5.84$5.91232.43K
Oct 29, 2026$6.05$6.16$6.00$6.09274.57K
Oct 28, 2026$5.76$6.03$5.68$5.99428.4K
Oct 27, 2026$5.56$5.8418$5.52$5.78376.78K
Oct 26, 2026$5.58$5.655$5.52$5.55242.66K
Oct 23, 2026$5.46$5.66$5.39$5.59262.03K

Latest OBIO news

The latest Smart Investors Daily articles mentioning OBIO.

OBIO research

Overview

Company profile and research snapshot.

Company profile

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$12.00
Implied upside
—
Analysts
13
OBIO recent ratings
DateFirmRatingTarget
Nov 13, 2026HC Wainwright & Co.Buy—
Nov 13, 2026BTIGBuy—
Oct 23, 2026Chardan CapitalBuy—
Sep 15, 2026B. Riley SecuritiesBuy—
Sep 10, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 17, 2026

Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference

NEW HOPE, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, today announced that management will participate in the Piper Sandler 38th Annual Healthcare Conference being held December 1-3, 2026, in New York City. David Hochman, Chairman and Chief Executive

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.